Clinical Trials
82
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1890
Active, not recruiting
5
6.1%
Completed
52
63.4%
Not yet recruiting
2
2.4%
Recruiting
16
19.5%
Unknown
7
8.5%
No approval data available
- Washington State University researchers used artificial intelligence to find a cheaper, more efficient way to 3D-print the high-performance NASA alloy GRCop-42, avoiding the need to test over 100 million configurations manually. - The AI-guided approach identified six successful printing configurations in three months using just 40 experiments, printing the alloy at 500 watts of laser power for the first time. - The method could expand access to GRCop-42 for universities and smaller labs lacking specialized high-power equipment, while reducing energy use and costs. - The same AI framework holds potential applications beyond manufacturing, including drug discovery and other costly scientific discovery problems.
- Penn State College of Medicine received a five-year, $2.5 million grant from the Health Resources and Services Administration to launch a street medicine program serving unsheltered populations in southcentral Pennsylvania. - Washington State University secured a matching $2.5 million, five-year HRSA grant to establish street medicine rotations in Everett and Spokane for internal medicine residents. - Both programs aim to train the next generation of physicians to deliver primary, mental health, and substance use care directly where people experiencing homelessness live. - The initiatives respond to rising homelessness and opioid-related deaths, with Washington's homeless population growing over 40% statewide from 2018 to 2024.
- A new non-hormonal male contraceptive implant called Adam has demonstrated effectiveness for at least two years in initial clinical trials, with no sperm detected in participants reaching the 24-month mark. - Developed by Contraline, the water-soluble hydrogel is implanted in the sperm ducts through a minimally invasive 10-minute procedure, preventing sperm from mixing with semen while being designed to eventually break down. - The company plans to begin Phase 2 clinical trials in Australia later in 2025, with researchers noting this represents significant progress in expanding contraceptive options for men beyond condoms and vasectomies.
- A double-blind, placebo-controlled study found that cannabigerol (CBG) significantly reduced overall feelings of anxiety in cannabis users. - Participants reported no intoxication or significant side effects, and CBG did not impair cognitive or motor functions. - Surprisingly, CBG enhanced verbal memory at 45- and 60-minute check-ins, a finding that warrants further investigation. - The study provides initial scientific evidence supporting the anecdotal use of CBG for anxiety relief, distinguishing it from THC's effects.
